ABDX — Abingdon Health Share Price
- £14.19m
- £13.20m
- £4.05m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 12.64 | ||
PEG Ratio (f) | 0.3 | ||
EPS Growth (f) | 73.99% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 7.82 | ||
Price to Tang. Book | 8.17 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 2.66 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -87.27% | ||
Return on Equity | -76.65% | ||
Operating Margin | -44.5% |
Financial Summary
Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | £m | 2.28 | 5.24 | 11.62 | 2.83 | 4.04 | 18.9 | 21.7 | 12.26% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +39.13 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Abingdon Health plc provides lateral flow contract development and manufacturing (CDMO services) and related contract services to an international customer base. It offers its services to an international customer base across industry sectors, which include clinical, self-testing, animal health, plant health, and environmental testing. Its segments include Product sales, Contract manufacturing, Contract development, and Regulatory. Its regulatory services include technical file build, regulatory filing support, implementation of quality management systems and quality assurance. The Company’s CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Its Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests to enable consumers to manage their own health and wellbeing.
Directors
- Christopher Hand NEC
- Christopher Yates CEO (43)
- Melanie Ross CFO
- Scott Page SEC
- Lyn Rees NID (47)
- Mary Tavener NID
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 16th, 2008
- Public Since
- December 15th, 2020
- No. of Employees
- 82
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 126,716,822
- Address
- York Biotech Campus, Sand Hutton, YORK, YO41 1LZ
- Web
- https://www.abingdonhealth.com/
- Phone
- +44 1904406050
- Auditors
- BDO LLP
Latest News for ABDX
Upcoming Events for ABDX
Full Year 2024 Abingdon Health PLC Earnings Release
Abingdon Health PLC Annual Shareholders Meeting
Similar to ABDX
Advanced Medical Solutions
London Stock Exchange
Angle
London Stock Exchange
Aptamer
London Stock Exchange
Belluscura
London Stock Exchange
Cambridge Nutritional Sciences
London Stock Exchange
FAQ
As of Today at 19:02 UTC, shares in Abingdon Health are trading at 11.20p. This share price information is delayed by 15 minutes.
Shares in Abingdon Health last closed at 11.20p and the price had moved by -20% over the past 365 days. In terms of relative price strength the Abingdon Health share price has underperformed the FTSE All Share Index by -24.87% over the past year.
The overall consensus recommendation for Abingdon Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Abingdon Health does not currently pay a dividend.
Abingdon Health does not currently pay a dividend.
Abingdon Health does not currently pay a dividend.
To buy shares in Abingdon Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 11.20p, shares in Abingdon Health had a market capitalisation of £14.19m.
Here are the trading details for Abingdon Health:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: ABDX
Based on an overall assessment of its quality, value and momentum Abingdon Health is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Abingdon Health is 78.00p. That is 596.43% above the last closing price of 11.20p.
Analysts covering Abingdon Health currently have a consensus Earnings Per Share (EPS) forecast of £0.01 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abingdon Health. Over the past six months, its share price has outperformed the FTSE All Share Index by +13.51%.
As of the last closing price of 11.20p, shares in Abingdon Health were trading +13.66% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Abingdon Health PE ratio based on its reported earnings over the past 12 months is 12.64. The shares last closed at 11.20p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Abingdon Health's management team is headed by:
- Christopher Hand - NEC
- Christopher Yates - CEO
- Melanie Ross - CFO
- Scott Page - SEC
- Lyn Rees - NID
- Mary Tavener - NID